Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Quantifying ageing related cognitive decline and mild cognitive impairment

COGDEC

University of Ljubljana, located in a low R&I performing country, will partner with two internationally-leading organisations, the Medical University of Graz and KU Leuven, to expand the support and coordination capacity for national and European research in ageing-related decrease in brain functions leading to dementia. By 2025 more than 25% of...

Funding Programme
Start Date
End Date
Total Funding
€ 799 811
European Countries Involved

Quantitative super-resolution optical fluctuation and phase microscopy for structural and functional imaging of Parkinson's disease

funcSOFI-PD

The changing demographic is one of the greatest challenges in Europe. With an expected 25% of the population over 65 by 2030, the incidence of neurodegenerative age-linked diseases like Alzheimer’s and Parkinson’s is likely to increase. They severely impact quality of life and to date, therapies can only treat the symptoms. Oligomerization and...

Funding Programme
Start Date
End Date
Total Funding
€ 175 420
European Countries Involved

Quantum-enhanced nonlinear imaging

QuNIm

Many pioneering advances in medicine and biology require observation of the microscopic world with high resolution and without damaging the specimen. One of the most widespread techniques is multiphoton fluorescence microscopy, which allows full 3D imaging via optical sectioning, i.e., imaging of planes within the sample without the need for...

Funding Programme
Start Date
End Date
Total Funding
€ 1 979 704
European Countries Involved

Real world outcomes across the AD spectrum for better care: multi-modal data access platform

ROADMAP

Alzheimer’s disease is on the rise in our ageing population, and new, effective treatments are urgently needed. Currently, the safety and benefits to patients of potential treatments are assessed in strictly-controlled clinical trials. However, clinical trials do not provide information on the health benefits for patients in their daily lives in...

Funding Programme
Start Date
End Date
Total Funding
€ 8 210 381
European Countries Involved

Real-time imaging and mechanistic analysis of Tau fibril disaggregation in live cells

Tau DG RT-imaging

Age-dependent neurodegenerative diseases associated with protein aggregation represent one of the most important medical and socio-economic challenges of our time. With the extension of human life span, the prevalence of this group of diseases has markedly increased. Among them, Alzheimer’s diseases (AD) and other dementias have become the second...

Funding Programme
Start Date
End Date
Total Funding
€ 173 847
European Countries Involved

REAL-WORLD IMPLEMENTATION, DEPLOYMENT AND VALIDATION OF EARLY DETECTION TOOLS AND LIFESTYLE ENHANCEMENT

AD-RIDDLE

Alzheimer's disease (AD), the main cause of dementia, is one of the major global health challenges of our time. This disabling disorder affects 55 million people worldwide, with costs above $1.3 trillion. With 67 million people at risk for AD dementia (prodromal and preclinical AD) in Europe alone, it is a major unmet public health need, with...

Funding Programme
Start Date
End Date
Total Funding
€ 12 090 250

Regulation of APP Metabolism by ER-Associated Degradation

APPERAD

The pathological Ab peptide that accumulates in senile plaques in Alzheimer’s disease (AD) brains is derived from a precursor protein APP. Although etiology of AD is complex, genetic evidence shows that duplication of the APP gene locus leading to elevated levels of APP protein is sufficient to cause early-onset AD highlighting the importance of...

Funding Programme
Start Date
End Date
Total Funding
€ 75 000
European Countries Involved

Regulation of cellular proliferation in chronic neurodegenerative disease: Microglial proliferation and neurogenesis in prion disease

ProNeuroDeg

An important aspect of chronic neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, Huntington’s or prion disease, is the generation of an innate inflammatory reaction within the central nervous system. Microglial cells play a leading role in the development and maintenance of this inflammatory reaction, showing enhanced proliferation and...

Funding Programme
Start Date
End Date
Total Funding
€ 200 550
European Countries Involved

Regulation of iron homeostasis through beta-amyloid precursor processing in neuronal health and disease

APP & IRON TRANSPORT

The life essential element iron is required as a cofactor in central nervous system metabolic processes, but unbound iron catalyzes the production of toxic reactive oxygen species. Neuronal iron accumulation is a common pathological feature in the cortex in Alzheimer’s disease (AD), the substantia nigra (SN) in Parkinson’s disease (PD), and the...

Funding Programme
Start Date
End Date
Total Funding
€ 100 000
European Countries Involved

Remote Assessment of Disease and Relapse – Alzheimer’s Disease

RADAR-AD

There is an urgent need for novel approaches assessing functional decline in early AD. The main goal of the RADAR-AD project is to develop a digital platform to detect subtle functional deficits in early Alzheimer’s disease (AD) individuals by integrating a meaningful combination of smartphone, wearable and/or home sensor based parameters. The...

Funding Programme
Start Date
End Date
Total Funding
€ 7 640 145

Repurposing a human drug to treat Alzheimer’s disease

Re-TauAD

Alzheimer’s disease is a major cause of disability among older adults and represents substantial financial and human costs to patients, families and societies worldwide. Currently there is no cure for Alzheimer’s disease. Thus, novel effective treatments need to be developed that target the root causes of Alzheimer’s disease, in particular the...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Research empowerment on solute carriers

ReSOLUTE

Transport proteins are the gate-keepers of our cells, effectively controlling the flow of nutrients and other molecules across the cell membrane. With over 400 members, solute carriers represent the largest class of transport proteins. Yet although they have been implicated in diseases ranging from Alzheimer’s disease and amyotrophic lateral...

Funding Programme
Start Date
End Date
Total Funding
€ 23 850 000
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).